Perwyn has appointed Chris Pape as Portfolio Director and member of the the firm’s Portfolio Committee. Pape will be based in Perwyn’s London office but will operate across our portfolio.

Andrew Wynn, Founder and Managing Partner, says: “Chris is a great addition to the team and both sides of our business, Private Equity and Growth Capital, will benefit from his considerable expertise in supporting corporates and their management teams on the value-creation journey. This includes strategic growth projects, M&A, integration, upgrading systems & processes and refinancing projects. His input will be highly beneficial to help us scale our engaged partnership investment model as our portfolio grows in Private Equity and Perwyn Growth Capital.”

Prior to joining Perwyn, Pape was a Director in the Restructuring Services team at Deloitte LLP where, as a multi-disciplinary project director, he led a range of projects. These primarily focussed on assisting corporates and their stakeholders to navigate business opportunities and challenges. Pape operated in a range of sectors; most notably including food manufacturing, retail, consumer products, logistics and infrastructure. Clients and mandates included a wide range of businesses including private equity backed businesses and large corporates, as well as listed companies.

Recent projects include a GBP15 million senior debt PE backed transaction for a mid-market casual dining business. Pape led the workstream to align stakeholders on a re-opening plan following closures during the Covid-19 restrictions along with a range of contingency re-opening options.

He also recently managed the financial restructuring and senior debt facility extension for a listed company with a turnover in excess of GBP800 million, alongside an equity raise to provide the business with sufficient headroom.

Pape has also been involved in the senior debt facility extension and renewal for an international e-commerce fashion retail business; assisting a large consumer group with the strategic acquisition of an e-cigarette retailer; and the reorganisation and integration of a biotech business following the acquisition of three businesses that operated in similar fields.


June 2021